Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Now the purchaser has been known and it is a fierce Chinese telecom & smartphone company selling the most gear for today's high speed communications and more phone sets than Apple around the world.
It is the same company whose CFO Meng Wanzhou was arrested in Canada at the request of the US early Dec and is now out on bail... fascinating story still unfolding... due to Donald Trump's trade war with China...
Huawei, a private company with huge financial resources, which has invested more research funding than most western companies, one of the reason for its spectacular ascendance, thus at ire of Donald...because it is pausing to dominate new generation of communications -- 5G, etc
Politics aside, the company seems not to use the land it just purchased for making new generation of gears or fancy smartphones, or expanding its UK research base into the newly purchased land, instead it seems to allow NWBO to do all the necessary work for commercial use in the future, 20+20 years at least.
One implication is it may want to diversify its business and get into biotech and this is just a first step.
So it seems money may be no longer a problem because I don't think this land purchase is the first and last from Huawai or other biotech companies from China due to the publicity brought about by this deal to potential Chinese companies.
Besides, with the money in hand, Linda's hand has strengthened and she can make deals upon deals with other companies, toward eventual buyout by a multinational big P.
Without even a bit of worry about the demise of the company, anyone including wolfpack will eventually come to realization:
NWBO's success is an eventuality and unstoppable!
Linda ought be given maximal flexibiliy possible in terms of when exactly the trial will be locked and topline data be published.
The reason is quite simple: the only thing wolfpack has not been paniic yet is they know there is no imminent danger of topline data or its equivelent like substantial interests from long hedgfunds, or substantial lisence deals, buyout, or the like, as there now will be no concern whatever of the demise of the company for at least one or two years due to the recent secured funding from the sale of property.
Unless there is a mole in FDA who is feeding the wolfpack of inside information, in my opinion the only hope for the wolfpack to not be panic is a clear guideline from Linda.
If you are longs who do not depend on flipping shares to average down and have hold the opinion that no matter what the trial will be a success, and the the treatment will be approved, I don't think it will be hard to not give her all the resorts she can have.
Because of wolfpack, we have been suffering too much; the patients have been suffering too much; and the general investment community have been deprived of true and correct information about this company and its disruptive and promising immunotherapeutic platform. So it's time to give Linda the trust and means so as to uproot the wolfpack once for all, because it is the best interest of all stackholders and patients.
I believe we are near the truth\news, and I have no problem to wait a few more months if we have to.
The way LP/LG put out a news piece in ambiguity regarding unblind days obviously has its reasons -- I am holding why at this time!
The property transaction suggests the deal is signed with a big P for license right of only L, and the way or term it is at this time is provisional -- the big P would only take a friendly risk which is all written in the terms suggestively.
Until a definite signal takes shape, certain, the P would emerge and the deal would be finalized -- either a license deal or a buyout. All depend on
a sudden truth -- a yielding of authorities to fact and truth.
Until that day, we will continually see ambiguity, or total silence.
I prefer the latter, but doubt it (Linda has failed me by behaving exactly like a normal CEO, which most in this board love to have, but not me).
Have made my minded, the only thing I can do is buy as long as I have funds!
Buy
[Referred to Basin Street Blues's post] regarding naked short practice here of nwbo, your opinions and analyses are pure nonsense!
Even a kid can infer the naked shorts are alive and well even after nwbo delisted from NASDAQ to OTC. Linda's previous toxic financing/dilutions just exacerbate the situation.
No time to detail my opinion, interested check back my previous posts regarding naked short activities attacking nwbo.
Very interesting, people even the ones making living by trading are blind, and brain dead regarding this issue, and it is appalling!
Regardless, the share price will appreciate reflecting on the fact we have known today. Wolfpack just hopes we don's have a momentum, and that's why they pour cold water (naked short selling) at any good news in a very patterned sneaky way.
Time to go and buy (not misspelling)
So the company has further matured data which is again encouragingly positive in nature
-- the company ready to move to close the trail, not multiple stages and multiple months for each stage instead it is a process of "months"
-- the UK property sale is once again a slap on faces of naysayers/wolfpack who have said the property is almost useless or a bad initial purchase
All in all, it seems an ultimate buyout plan is in play. Good for investors and good for patient!
It it feasible and/or more powerful to make DCVax-L vaccine from DCs extracted and isolated from healthy bloods that can be readily obtained from healthy donors or from general blood bank, cultivated and mixed with patient's tumor mass, ie the same way with only the difference being the source of bloods for DC.
So the very invasive blood procedure can be eliminated, and the vaccines can even be made for patients with much worsen conditions which was previously impassible
Did the last dozens of patients use such vaccines?
Ignorance or imagination is boundless?
Nobody posting it's gonna be a very good day!
I am talking about nwbo of course. Thanks for saving lots of time!
Hi maverick_1,
Good luck to your new endeavour. Remember to come back to congratulate on us successful nwbo longs when topline data are released or a very substantial financial deal is made public, either a buyout or something very substantial.
Hi md1225,
It's reasonable to diversify considering you had held close to two million shares. Good luck to your new endeavour too.
I had continually added more shares. Now is more right time to add after all the new developments including the refreshed interim data, and those sited by others.
Only thing sucks is Linda's evergreen greediness. I am proud I didn't vote for her the last time, and I will find ways to combat her excessive greediness, meaning retail investors have not received due, or even a fraction of the respect compared to her greediness.
Be prepared to buy more at every pull back.
The dynamic has changed for the company Ladies and Gentlemen, despite the “evergreen’ greediness of Harvard educated chick Linda Power.
In regard to the incremental increase of option pool disclosed in an 8k Friday, nothing you can do with it; it’s perfectly legal; and it is a demonstration of chick’s dexterity. Nonetheless, I do believe bad karma will get the chick in life and it’s just a matter of time, if she has not taken care of her vast numbers of retail investors in a fair way.
Nonetheless, the dynamic has changed thanks to the revealed beautiful continually improved blinded interim data sets as of 2017 and 2018; to chick’s series of moves, including forced conversion, the unbearable multiple months of long dying quietness, etc,
As a result, it may have borne the fruits. For example, the late stage multiple parallel negotiations for substantial alternative potential financing disclosed in a recent SEC filing.
In addition, the chick has recently declared the time is now to have the data analyzed following about-to-initiate or already-on-going four multi-month stages, which in any way and logic, must be four parallel processes and can be conducted simultaneously. For most company, it is a mere within three or four month task. Again the chick has demonstrated her dexterity to reward her employees with a cheap option exercise price of $0.25, instead of $1 if she had had a normal news release of the same content, while preventing any legal liabilities in case the chick’s promise fails to deliver, and if things pan out beautifully later, she will be complimented for underpromise and overdelivery.
Regardless, the dynamic has changed. Something and a lot of things are definitely coming into fruition in the horizon, in both finance terms and promising topline trial results.
In life, we have learnt we have to swallowed something because simply we have no choice; the chick has a bitter deed for us retail investors to swallow, but the open question is does she also have a much sweeter, much more grandiose fruit for all us to share.
The answer is a resounding yes so it’s better add more when the price languishes or simply sit back and enjoy the otherwise mostly positive and rewarding journal.
Yes, the dynamic has changed despite Linda being a sucking chick, but don't complain the chick has not given you a hint for what is coming.
DYNAMIC HAS CHANGED! Quality food takes time to digest. Shorts are toast!
First of all, today's data point of 3-year OS for blended population of about 28.2% is once again a testimony that DCVax-L works, and works beautifully, and the trend of an increase over 2017 3-year blended OS of about 25.4% is expected if the vaccine is working.
Since the data was taken as of the spring, the data will definitely increase when data was locked which I suspect it happened in August.
As long as manufacturing improvement is concerned, the few posters who have talked this to exhaustion seem to have no basic grasp on clinical trial requirement, particularly the registration phase III trial.
So all those manufacturing speculations are just of ill-knowledge. Of course the manufacturing process has been improved, but the suggestion of adding those improvement into the existing trial repeatedly is just nuts despite good intention.
Today's data point is huge coupled with anticipated "substantial alternative potential financing" deal or deals in the near future, which is at least one more nail down on the wolfpack coffin.
This time Linda seems to finally have something in a row.
Simply put IMHO that Linda has blatantly filed to SEC the reason for the delay of Q filing so those parallel discussions with different third parties for substantial potential (this is the only word I don't like) financing are real and should be indeed late stage. Now less than 24 hours later, the Q is filed to SEC, which can only mean that the process, i.e., discussions are continuing and Linda would not expect the deal or deals can be concluded in five calendar days, or she simply wants to give an impression that she is not in a rash to close a deal or deals.
On the other hand, if the deal or deals are closed before five calendar days and the Q is filed then that or those substantial financing deal or deals will be buried somewhere in the Q, such as in a footnote disclosing that or those material news, which is not desirable in any way.
So a better way to do it is to close those deals and file to SEC in a separate filings such as K filing, and that will make the news more substantial and significant.
SO I expect one or several 8-k form filing to report those deals or deal in the near future, with Monday the earliest because one deal can be closed technically anytime after the Q filing, which is this evening.
If we see trading halt for those kinds of filing, that would be really substantial.
Has Linda had other news in her disposal besides the above?
Two things: [edit: not intended to reply to scotty3371, but for independent post]
1. The White Paper
It confirms MOA of DCVax-L supported by clinical evidence, for example the favorable delta compared to SOC, Novocure, etc. With a clear MOA approved, the success of underlying trials is almost certain.
The beauty is not just that for DCVax-L, but it is shown that by tweaking or modifying and/or combination with other agents, DCVax can extend benefits ten to hundred of times potent, which indicates much larger potential in the future.
So if DCVax-L is worthy of 50 billion cap, 5-10 multification of that is reachable for DCVax platform including D, which will be a huge market potential
2. Trading as usual indicating the control of wolfpack. For instance
Bid
CDEL 0.2099 22,515 09:58
CSTI 0.202 100,000 09:42
Ask
OTCX 0.21 5,000 09:30
CSTI 0.21 100,000 09:56
The question is WTH is it important or of any sense if one wants to buy 22,515 shares asking 0.2099 when the ask is only $0.0001 higher than your asking price with tons of available shares.
Without volume and continued enthusiasm or news, the wolfpack will still have your lunch.
you have it right. The best Linda Powers can and shall do is to talk to regulatory bodies, while ignoring all noises, either shareholders or not as much as possible.
As long as there is no leak, she will have no problem, and it seems there is no leak.
Thanks God, I like to buy more.
Oh, let it be, and let it be. This is an investment board, not a competition of who is right and wrong on what board.
Several characters in this board seem care that more than valuable information which can be used to make a better investment.
See, even a broken clock is right twice a day.
What's important is is this trial a final success so that it can extend patients life, and so that we investors can make money from it.
I believe it is, and we will and even more than just that judged by its MOA.
I saw you quoted the same in iVillage too. If you really want to get a full picture of what Dr. Linda thought about this issue at that time years ago, see below her email (courtesy of Sentiment).
"Question
Dear Dr. Liau: In your video last week (and also last year), your comments seemed quite positive about the patients living longer, but last week you also seemed to say that DCVax would not be able to get FDA approval. Is that what you really meant? How could that be the case if patients are living longer? Would love to have clarification on this issue
Thank you in advance for your time .
Xxxxxx xxxxxxxx
Dr. Liau's answer
Hi Xxxxxx,
Yes, the patients do seem to be living longer with DCVax; and no, I did not mean to say that DCVax would not get FDA approval. I was making the point that, whether or not the study fits a particular category endpoint, there should be a way to get approval if the data shows that the entire group of DCVax patients (in both arms) does better than concurrent/historical controls who have not gotten DCVax.
Hope this clarifies the issue.
Thanks,
LL
Linda M. Liau, M.D., Ph.D., M.B.A.
Professor & Vice Chair of Neurosurgery
Director, UCLA Brain Tumor Program
UCLA Department of Neurosurgery"
The beauty of this trial is that even LL has not expected the trial could be extended this long today when the last patient has almost been enrolled three years thanks to another Linda's stubbornness and determination, which may even provide ss differences between various groups such as the early and late treatment groups.
This will soon be an unprecedented data rich trial ever in history.
For the sake of your constant efforts you have made in this board countering anything positive regarding nwbo, I can only say this to you:
If you have a shredded bit of real time experience in small biotech investments, you would realize that for any and each dump, the holders of the shares to be dumped, i.e., the vulture funds who hold those vast numbers of nwbo warrants specifically, would have always hyped it and then come the dump.
Where is the hype you have seen in this stock besides this message board, man? They can hype this stock to much higher price via buying wiling and readily available journalists, bloggers, or people like you, etc., to hype the price with constant speculative news, rumors, buyout, merger, partnerships, night club hearsay or hearsay, and you name it, in any places and manner possible.
Then, the price would have rise, while innocent investors would have been doped buying in the hype, ...
That's the way and only way of a pump and dump, which has not happened with this stock, and it seems it will not happen. This is a big plus indication, along with forced conversion, no public financing but Linda's own money loan, of course the interim blinded data.
So it seems warrant holders have been unwilling to spend a penny to hype this stock they want to dump or already dumped, nor our dear leader CEO Linda Powers who is as quiet as dead!
So what on earth is going on and happening?
Well, I can tell you what has been happening recently: LP is super busy working on her master plans to bring DCVax-L to undeniable success, and she then will go after those who have committed criminal acts against this company and its share holders and suffering patients. She has no time to watch share price and has no interest to get distracted as data have been scrubbed, talking with regulatory authorities including FDA, etc. We are approaching the major inflection point which must be good, or super good.
For that, I bought 10k shares to add to my large position to conclude my once a day post.
It's particularly important to have someone called Les to have at least the face value of the report of the talk to talk about for fun while we are obviously in waiting, waiting and waiting for something of substance to happen, instead of talking or debating about some imagined trigger of event rate, or rate of event accumulation or the like
It's blinded. There may be signs for trending of the trial, but there is definitely no telling of the trial results, let alone statistical magnitude, ss or not.
Anybody reporting conservation with Les at this point is very much appreciated!
He is a pro nwbo now obviously by the paper he provided.
18 months v 23 months
inferior process/manufacturing
almost ad hoc preparation v decade of painstaking invention, trial and error, progressing, secret sauce
small data set/patient population
failed to or not intended to catch long-term survival
.......
unless the air is different in NY City and Los Angeles or London. And anyone can definitely list a long list of differences
At least I can
All point to a very successful DCVax-L trial results
Nothing new here, nothing.
The fact is that we don't know if L will be a definite success (we include Linda Power) until the last shred of information unlocked from unblinding. You may have reason to not believe many things Linda has promised or said, but you can trust her when she said the trial was still blinded. That's a redline nobody wants to pass if he or she wants to get the treatment approved by FDA.
The good news is the blinded interim result publication, which suggests L could be more than 80% success if the control behave the same or similar to all the precedent trials: below 20 months from surgery; coupled with 1/3 of population in the L trial who have performed very well, with no known reasons to explain but the efficacy of L, now that needle can move to 90%; if the trial indeed can capture the long tail, I am certain L will be 100% approved by FDA.
If she doesn't have the confidence, she would have diluted again and again in the past several months; Instead, the company is being run with loan;
If she doesn't have the confidence, she would have launch at least one if not several combination trials or standalone D trials for multiple indications.
She has given too many signs to you. No one should blame her for not communicate enough as long as you have ears, or to be exact brain.
She will surprise the market as observations testify once again not many investors deserve multibaggar, let alone 50 ~ 100 baggar.
There are always greener pastures for you folks. Fighting for one or two cents of price movement is pathetic if not pitiful.
Kam, honestly I really don't know. What I know is the approximate eventual market cap if the trial results are indisputably positive, which shall be at least 5 billion (about $5 per share), or about 3 billion ($3 per share) if the results are very positive but with some caveats, or about 1 billion ($1 per share) if the results are dubiously positive, or a few million if the results are indisputably negative.
In the meantime, too many factors could come into play, including how big will the squeeze be, are there any big name funds coming onboard, etc., let alone about future speculation: how about other indications if L is successful for GBM, how huge will be the market potential of D, etc.
Anyhow, one simple and mostly accurate estimation about future price is to compare nwbo with other similar companies in the similar sector.
Good luck to you and all nwbo long.
Odds, very odds that anyone would believe the company would meet NICE date of submitting evidence support unless he or she believed the company had secretly unblinded data some months ago.
Com'on, sell your shares and move to other normal companies where no high IQs or common senses are required.
BTW, evidence support means unblinded data which would testify evidence of efficacy.
If the company decided to unblind data when last patient has been 36 months after surgery, one would expect two to three months at least to have the topline data ready, which means October or November this year (August + 2 or 3 months), or 36 months after enrollment, one would expect topline data in and around Jan or Feb 2019 (November + 2 or 3 months).
There might be some secret activities going on behind the scene, which are likely but not probable.
If there is still no dilution from the company or as long as no dilution from the company although it can do it readily thanks to all your generous yes votes, some positive things must have been happening:
The forced conversion is one; second, no pump but silence; third, no other trial launch distraction; ... which all mean confidence, and anytime you are in doubt, go read the blinded publication again!
In this stage and after the company has been unfairly assaulted from any angles in anyways, Linda ought to operate in stealth continually.
A surprise is for the good of patients and long suffering long investors, Linda, you must remember that.
With half of my family nets have parked with this company resulted from endless hours of DD, I am confident enough to continually add shares until after topline data is announced.
BTW, what's our MC? Slightly over 100 million? Wow, please sell.
Sentiment, sorry to hear it and glad your husband is in recovering. You are one of a few persons in this board who are genuine, honest and smart who I like to read their posts.
You are brave and blessed too. My prayer for your and your husband.
I will ride this to the end with you and other longs. Like you when I am absent, nobody should interpret that as I have sold.
Take care!
Notice those inspicable characters in twitter who have all gone since yesterday. In the past they would come earlier than most so as to put a dent or impression of any company's sec filing or news with negative spin.
The one-eye funny looking "expert," the CFA/CFP guy, the guy pretending smart holding his chin, and the like have all gone not leaving even a word of comment on yesterday filing.
What a convenience, even Jerry in iv can only talk something like RS, and then admitted it is of a slim chance, unless the company wants to be relisted in NASDAQ (Gerry get real!)
Nothing has changed until it is changed.
Happy buying!
What it says:
Date Timestamp Price Volume Tick Direction Change
09/13/2018 09:31:47 0.185 5,555 -0.00
09/13/2018 09:30:04 0.186 7,400 0.01
09/13/2018 09:30:03 0.175 100 -0.01
09/13/2018 09:30:02 0.1855 2,500 0.00
09/13/2018 09:30:02 0.1855 100 0.00
It shows manipulation as always. I bought 18K yesterday completing transaction for hours, intended to see if really somebody wants to sell.
Conclusion: absolutely not. It's all walk down for unknown reasons.
So for me it is buy as much and many as you can afford!
Just done some travel around the world one month ago, and have since quietly waited, waited and waited -- still have tons of patience waiting for the fate of my investment, not a share sold and will not until the results.
BTW, came across an interesting article:
https://www.washingtonexaminer.com/linda-powers-a-keen-eye-for-the-right-opportunities
[part of it:]
Linda Powers: A keen eye for the right opportunities
by Katie Wilmeth
| August 11, 2006 12:00 AM
Print this article
Linda Powers knows an opportunity when she sees it.
The co-founder of Bethesda-based Toucan Capital has made a career of seizing new opportunities and making them work for her.
From an active career in corporate takeovers in the 1980s to a presidential appointment at the U.S. Commerce Department during the first Bush administration and, finally, to her current career investing in fledglingbiotechnology companies, Powers has had a front-row seat for some of the hottest developments in the business world over the last 20 years.
Seventeen Years Later: Remembering 9/11
Watch Full Screen to Skip Ads
Now, as one of the country’s most successful biotechnology-focused venture capitalists, she has been tapped to lead Maryland’s high-profile Stem Cell Research Commission. The commission is overseeing the distribution of a $15 million fund for Maryland-based firms focused on stem cell research.
The 50-year-old Potomac resident has jumped from one big opportunity to the next throughout her career — always seeming to leave at just the right time. She started her career at the law firm Latham & Watkins in New York, where she specialized in hostile corporate takeovers. Just as that hot trend was fizzling, Powers was appointed Deputy Assistant Secretary for Service Industries at the Commerce Department. After four years, she was hired at Enron, but left to launch her own venture capital firm in 1997 before the now-infamous scandal broke.
"I’ve been lucky with my timing," Powers said.
Powers, who co-founded Toucan Capital with her husband, Bob Hemphill, said the decision to start her own business was a natural step in her career trajectory. "I looked at the landscape and it seemed to me venture capital was an interesting area of opportunity."
Toucan’s first fund invested in a variety of companies, but its third fund, at $120 million, focuses solely on seed and early-stage bioscience companies — one of only a handful in the U.S. focused on start-ups.
"Biotech has the longest time frame and one of the biggest risks, but at the same time biotech provides great returns," she said.
Toucan currently has investments in 10 stem cell companies, including more than $60 million in Maryland-based firms.
As the new chairwoman of the 15-member commission, Powers will help define the state’s role in the hotly-debated stem cell researcharena.
"My favorite thing is working with scientists and first-time entrepreneurs and helping them take some kind of research results and turn it into a real product for the real world," she said. "I think success stories come in all shapes and sizes … but the key thing [for the Commission] is to do something that advances the science and/or advances the research to get something to the bedside."
[about her husband according to bloomberg:]
Mr. Robert F. Hemphill, Jr., also known as Bob serves as the President and Chief Executive Officer of AES Solar Power, LLC. Mr. Hemphill served as the Chief Executive Officer of AES Solar Energy, Ltd. He served as Acting President of Asia & Middle East and Executive Vice President of Strategic Initiatives at The AES Corporation. He has more than five years' experience in seed and early stage venture capital investing and over 20 years' experience in corporate operations, including two successful IPO’s and dozens of project and corporate financings, both domestic and international. He co-founded Toucan Capital Corp., and Toucan Capital Fund II, L.P. and served as its Managing Director from June 1996 to February 2004. He served as the Chief Executive Officer and President of Silver Ridge Power Inc. Previously, Mr. Hemphill was a Co-Founder at AES and a Senior Manager for over ten years. He served as an Executive Vice President of Global Development at AES Corporation since February 5, 2004, an Executive Vice President from 1982 to June 1996, a Director from June 1996 to February 5, 2004. He served as an Executive Vice President and Chief of Staff of The AES Corporation form February 2004 to march 2008. Mr. Hemphill served as the Chief Executive Officer and President of AES Transpower Pvt., Ltd, where he served as a Vice President of Project Development, from 1982 to 1984. He was an Executive Vice President of Business Development at AES Wind Generation LLC. From December 1993 to February 1, 1995, Mr. Hemphill served as the Chief Executive Officer and President of AES China Generating Co. Ltd, a Vice Chairman from February 1995 and a Director from December 1993. From 1984 to 1987, he was employed as a Senior Vice President at AES. Mr. Hemphill helped start AES Corp. in 1981 and in concert with his two partners, built it from a three person, one million dollar start-up to an international corporation with electric power generation and distribution and telecommunications activities in the United States, Europe, Latin America, Asia and Africa. Prior to Mr. Hemphill’s tenure at AES, he served as a Deputy Assistant Secretary of the United States Department of Energy, with responsibilities that included energy research and development planning and budgeting. Subsequently, Mr. Hemphill served as a Deputy Manager of Power at the Tennessee Valley Authority (TVA). He served as an Executive Vice President of Business Development at AES SeaWest, Inc. Mr. Hemphill has more than 25 years of experience in senior management positions in small and large corporations and government organizations. Mr. Hemphill serves as a Director of Reactive NanoTechnologies, Inc., Phoenix Motorcars, Inc., Selecterra.com, the Smithsonian Institution’s National Museum of American History, the Advisory Board of Optiglobe, the Advisory Board of Venturehouse, Trophogen Inc., and Chameleon Technologies. He served as a Director of Knova Software, Inc. (also known as ServiceWare Technologies Inc.) since June 2001. He served as Director of Altair Nanotechnologies, Inc. , from May 2007 to November 19, 2009. He served as a Director of Silver Ridge Power Inc. since July 12, 2012. Mr. Hemphill holds an M.B.A. from George Washington University with a specialization in Finance, an M.A. in Political Science from UCLA and a B.A. in Political Science from Yale University.
Unfortunately Linda is here to stay for a long haul, but she will be our friend and guarding as long as L and/or D has a decent chance of regulatory approval, because simply by having L and/D approved she will not only leave a mark in history but get really rich.
Yes she has demonstrated she is a selfish, greedy American capitalist, and even one who is short of a vision, contrary to what she put in her curriculum vitae.
And by making things worse, she and Les have consistently lied to investors and media, and have rarely done their jobs, fulled their fiduciary duties as leaders of a publicly traded company.
Those mentioned above are known to all, needless to repeat any further.
Nonetheless, at this junction point and after reading the recent published interim blended data, I feel time is now to lay trust, perhaps for the last time (for me actually is the first time, as I had been one of the persistent critics on Linda, particularly in her poor performance in securing funding and protecting share price) upon her:
We are faced with mounting difficulties from perhaps corrupted regulatory employees, the often and long-talked wolfpack, and even those funny individuals who trade for one or two pennies' swing with mood shifting like changes of baby diapers (thus the word funny), and those who persistently poke the company with any negativity, FUD imaginable and unimaginable regardless.
So I have placed my full trust upon Linda Powers and believe she will do the best for the company, thus us investors and herself, and for moving this innovative, safe and effective treatment into regulatory approval.
So I am willing to sacrifice and let her the free hand to operate. We have to defeat and totally cripple all forces negative and destructive against putting DCVax-L into regulatory approval.
My only hope of course is that she must not dilute us heavily and better borrow all the way to regulatory approval.
SHE KNOW MORE THAN ANY OF US ON WHAT ARE HAPPENING BEHIND THE SCENE AND CAN THEN MAKE THE BEST DECISION!
Sorry fellow members: I have no longer followed this board post by post. It's just waste of time.
I continually add shares as long as the share price, reflected on low market cap of around $200 million in a fully diluted base (today's it's about $100 based on around 440 million shares) is low, because the huge upside potential has not changed, which should be at least in the range from $3 to 10 billion if topline data are released and they are positive:
We already know DCVax-L is safe, pristine safe; and regardless what has happened with the halt, the design, the changes in protocols, the overdue primary and/or secondary endpoints, the baseless accusations, new and old, the message board endless "experts" opinions on everything, real or imaginable, the blatant endless attack on share prices,the DCVax-L will be approved by regulatory authorities, including corrupted FDA (the recent two articles appeared in Science just a couple of days agao are once again testimonies that FDA is just big pharms' toy and it is often against small biotech companies).
If one follows developments in treating GBM, and reads the recent published interim blended results of DCVax-L in treating GBM as of last year, he/she will conclude the chance of DCVax-L shows efficacy is pretty much high, above 80% IMHO.
For a $0.23 per share stock at market cap of slightly over $200 million in a fully diluted base, and an odds of approval of at least more than 50% in treating one of the toughest cancers, all the doubts, bashing, so-called discussions are just pitiful.
The company has said it has been in discussions with regulatory bodies all along since around the temporary halt for new patient screening, and it seems that process is still ongoing, perhaps with some twists and turns, new subjects, new contents, etc.
I trust the company will have definite communications with its investors after that process is complete successfully. If not, I also believe the company will unblind the trial anytime within this year.
And with concrete data showing both safety and efficacy, even the corrupted FDA will have to save its face in the face of light, public opinions backed by solid trial data.
That's day is coming fast! In the meanwhile, Linda has my confidence to surprise the market!
BTW, it is common sense and empirical that a small biotech company will usually launch other trials, in any other indications, in any forms, either combination or not, if it doesn't have confidence its pivotal trial will be a success. Anyone who has invested in small biotech companies knows and see this for at least multiple cases. Linda doesn't have problem to dilute us heavily to launch one or two promised combinational trials if she doesn't have confidence in success of DCVax-L trial. So far she has focused on L, which I am very happy about it.
Does a potential paradigm shifting cancer treatment vaccine deserve only a couple of hundred million market cap!
One must be nuts debating when it is the good entry point, not buying more if still having dry powder to disposal, not covering naked short positions, not giving up useless endless unknown negative motives and actions!
All those science discussions are boring, wannabe in nature and just distraction, wasting time and doing no good for any investors.
MOA of DCVax-L is clear and easy to understand; we have had some clinical data, including the recent publication about still blinded data.
Nobody in the history of drug/vaccine/treatment developments has ever managed to predict outcomes of a blinded trial correctly, if not by chance once or two or by playing statistic odds like AF, from all genuine and wannabe experts of all sorts or so-called biotech analysts or journalists.
Waste no time, get the message out; contact VIPs, particularly those who have had vast resources on disposal to compensate incompetent Dear Leader Linda Powers who has failed to have even a single VIP to get into the stock, because she is stink of various dimensions. Despite that, as I have accumulated and continually added to my position with my nose pinched, some big fish will come onboard considering the great prospect of DCVax platform in transferring the landscape of cancer treatment, and of ten or twenty bagger of stock appreciation potential, which is of much more grandeur than the stinkiness of the management!
Next time when voting is coming, use brain but no fear to vote.
Dear Linda Powers may still have a shred of opportunity to win some respect from me: find a big fish to back our stock and/or make a surprise announcement of a short-crushed news!
As I have said before, an investment cannot be said to be difficult if it would yield multiple bagger, let alone 10 or 20 bagger to an average self-claimed MB investor. The majority of MB investors are noise, appear or disappear frequently like a baby diaper change.
With the next six months, absolute silence is fine to me if she can deliver.
"All theories that I have come up with may seem to be unlikely or far-fetched, but something caused that damn hold!"
Sabotage. That seems to be one reasonable reason for the halt considering why Linda and the co have so far kept quiet.
It could be a sabotage job conducted by one employee of FDA, even if that person has left his/her position or even left FDA, it has been and will continually be a very sensitive issue for the company to deal with, particularly for a small development stage biotech company which doesn't want spoil its relationship with FDA or ruin its chance for an FDA approved product.
Besides that, I cannot come up with anything that can explain the halt considering what we have experienced since the halt.
Regarding other issue about when to unblind or if data has been matured enough, I do agree the time for unblinding is now for the reasons which have been well discussed, but I would like to say it will make difference in terms of
numbers of patients who have experienced 2, 3, 4, 5 years of survival respectively. For instance, 40 patients or 50 patients who have experienced 5 years of survival out of total 331 patients apparently are not the same in terms of significance and power; And yes data can be continually collected as have been done for almost all other trials after topline/data unblinding. Definitely, there is still a huge difference.
Considering all circumstances, not only the odds of FDA approval but also ethics, economy, competition, etc., I do agree with most posters that it's the time to unblind.
It's a brilliant idea to publish interim blended data. Thank you Linda for that from the perspective of a long investor.
Today, enough data have been revealed from the publication in a credible and reliable way signed by 65 experts involved in the trial in the related field. What's more do anyone still wants in order to make a decision: either buying a position, adding more or go away.
For those who bash or pump for a few pennies, you are just noise.
The share price movement since the publication has made me certain there is indeed a huge naked short force behind the scene, and there is not even a single major fund which is long the stock. The Bigger is a peanut despite his publicity.
Linda is to blame for not securing even a single major fund in support. Nonetheless, I am happy with the publication, and has added more to my position at any opportunity time.
And I have been sleep very well, believing this platform will be validated for treating GBM in the near future first, followed by much shortened and accelerated approvals for more indications and stages thereafter. We are about to see a truly paradigm shift in cancer treatment spearheaded by DCVax platform.
I hope Linda can borrow the way to topline data release, and during the process, communicate at the minimal with the public.
When the data is announced, make sure it is conducted in a truly unexpected way.
The wolfpack, aka naked shorts, which I have not doubt on its existence by now, has to pay: pay to cover with very high share price, and pay for with legal punishment.
Let me rehash: DCVax-L is safe (fact), and it is efficacious (the existing data have strongly suggested it is, and the final validation will come shortly).
FDA has no excuse to not approve a treatment, which is safe and efficacious, let alone the one which will make patients have quality of life.
Buy as many as you can afford, go on a vacation!
Linda is being watched by SEC, wolfpack, and those who have had no position but post constantly.
I have my words for Linda Powers, the all great leader of nwbo land and the future cancer treatment vaccine platform for all solid cancers:
Please act once more against all common practice/procedures: don't announce trial lock, analysis (whether it is a material news or not, you can always find reasons to say otherwise), just come up a very brief announcement saying the trial has been unblinded, and some topline positive data;
Let the shorts once again dig a bigger hole after initial substantial share price appreciation, like a week or so;
Than, come up with a more detail but definite trial data. Then, we can only smell champagne opened by longs and burning smell of shorts for years to come!
Anyone now has had the chance to analyze the publication authored by around 65 experts, and the desperate one by two experts called Stupp, and Fine.
That's the base for a long thesis, if one still don't get it and still pays attention to a few pennies up and down.
They deserve only to watch the longs' champagne and shorts' burning years long party.
Linda heading in the right direction regarding today's borrowing -- Promissory Note, though the term could be better, but I have no complain.
I particularly appreciate not issuing any more shares at a low price. Thank you Linda for that!
This financing, in the initial principle of about 2.8 million, on discount of about 375,000 for 18 months at annual rate of 8%, giving the actual annual rate of about 16% after taking into account the discount, is a significant improvement from most previous loan by Linda herself, which has comparatively low annual rate, but potentially share dilution term.
The bottomline is if you believe the topline data will be released within reasonable time range, this high interest loan can be forgiven.
If she continues funding the company via loan instead of issuing large number of shares at low share price, I will be a willing buyer of more shares!
Hopefully, this 2.5 million is enough to see unblinding and release of topline data within next few months!
Longfellow, no need for any seriousness on that tweet. The doctor who tweeted that is a day trader who has been in and out of his nwbo position numerous times so has been his sentiment or "pumping or bashing" of the company.
I don't like what Linda Power has mostly done to this company, particularly the share price via unnecessary incompetent-derived dilutions, but there is one thing I have full confidence on her which is that she won't sell the company cheap.
Of course, after the data release (publication), a partnership deal or two are possible.
Regarding buyout, we should wait until final data publication.
[it's meant to respond to AVII's post}
I applaud your caution and civil way of discussing things, though I have been persistent suspicious on the root of all that, if you are talking about a stock with a potential revolutionary treatment for one of the toughest cancers of which the share price were $1 or a MC of about 1 billion fully diluted, then I may agree with you
But we know the MC is merely around 200 million fully diluted, the odds of this treatment of being approved increases significantly after the recent release of peer reviewed paper. Yes there are still uncertainties, but the potential reward/risk ratio has risen substantially.
I am not just saying, I again bought 20k this morning, on top of 100k in last week, on top of my already huge position accumulated over the years since German approval "fiasco."
And I intend to add more if price continually hovers in low band in the next few months until big news comes out.
Certainly, the staled Dynamic can shift anytime, and I suspect some big fish may be behind manipulation recently in addition to the usual and consistent wolfpack naked shorts, in order to start significant positions.
Even Woody may be behind it too for that long waited shift of everything we all have anticipated, and it will come!
In essence, we said the the same. I said I applaud Linda's new found honesty and flexibility (ie her appeal to anyone who can help, including Woody); and I also said Woody should "grow an inch taller," like a man.
I also said at the beginning of that post that Linda ought to do anything possible to reach out to anyone who can help. Woody should be a natural first person she must reach out.
If she can find someone or somebody find the company and is willing to take a significant stake of the company as shareholder or debtor with significant resources as backing, then the dynamics will shift right away; otherwise, we have to wait that day longer.
Anyhow, I like to see Linda surprise us in this front of course, but for my personal revenge, or long-suffering shareholders avenge, I would like to see her announce something truly substantial in a surprising way.
I believe all blocks have been in place. Some "smoke and mirrors" are welcome if that ushers in a truly surprised announcement.
Because with the publication/data, I don't think DCVax-L's eventual approval is out of question, so my naive part would like to see naked shorts truly get burn, and the only way to burn those bastards is to "attack" them when they are least prepared.
I have only one job for Linda to do, or maybe most likely she is finally doing that (her) job:
Go telephone, knock on the doors, or do any means of communications to big fund managers, or anyone who has immerse resources. Show them the science with available or not yet publicly disclosed data (after sign NDA), and the limit on your acceptable future structure of the company organizationally and financially.
With a great likelihood of FDA approval for GBM, and potential other indications in an accelerated track which will most likely happen after L is approved, there will be some big fish who want to make huge profits while making their names known for helping to bring a truly disruptive transformational cancer treatment platform into market and to tens of millions of patients.
With all the available data, which I am almost certain DCVax-L will be approved by FDA in the near future after the final unblinded data are published/submitted, along with Linda's recent personal appeal during ASCO presentation for help, which apparently is a natural and surprised change from her "go big or go home" of past mentality, I believe a dynamic shift is happening!
With any concrete source of financial support in any form of structure which will be beneficial to the majority of shareholders, that dynamic shift will come.
Until then it's all a swarmed naked shorts playground while SEC is watching with no action.(it is also a period any true longs with resources can accumulate a large position waiting for that shit, which will come sooner or later!)
As long as Linda can secure a solid financial backing, naked shorts will be belly up, and all shorts alive will be turned into unwilling longs. The price will be heading in its due course after an overshooting period baking the shorts, aka short squeeze.
We need that man or lady who is willing to come onboard; if Woody is a man, he should be that first person again! Lick your wounds, Woody, come on! Be a mature, brave man!
For God's sake, please make that dynamic shift happen ASAP!
Who the hell are interested in making/manipulating the PlusOneCoin Top Posts section?
There have surely been tons of actions since paper publication on 29 May.
What constitutes a PlusOneCoin post, and how to make it happen?
A new battlefield? Funny!
Ladies and Gentlemen: I solemnly announce with excitement we have a slam dunk success for DCVax-L trial in treating GBM patients!
The evidence lies in the long, fat tail in the making. Compared to mOS and mPFS, the long fat tail is much more of substance and meaning.
As a result, it will be useless to debate anything related to mOS and mPFS without realizing the fundamental significance of a long and fat tail of treated patients.
God bless! This is only the first step for a truly disruptive treatment with pristine safety profile and potentially unlimited efficacy implications for all types of solid cancers!
Quote from article:
["To date, we have not yet reached sufficient events (i.e., deaths) in this trial to justify unblinding. Nevertheless, since the vast majority (86.4%) of the ITT population received the experimental DC treatment at some point during the trial because of the cross-over study design, analysis of the interim data may provide early insight into the impact of DCVax-L on overall survival. A final analysis of the data obtained in this trial following unblinding will occur once sufficient events of disease progression or death have occurred to fully elucidate patient survival data in the tail of the survival curve[/u"].
Regarding the halt: Various speculations have been thrown out in the past, including two of my speculations. Nonetheless, one other possible speculation could well be due to company’s changed objectives to catch the full effect of immunization agent (DCVax-L specifically), reprehensive of a potential long and fat tail, in addition to the initial objectives of PFS and OS according to design and the subsequent amendment, for instance, the PFS difference changed from demonstrating ss for 6 months to 4 months.
As a result, the company might have conducted one or none of the two designed interim analyses, in addition to the one conducted for trial expansion on safety at 66 OS in 2014 in order to accommodate to the new objectives.
As a result, the company might have been in discord with DMC and/or FDA. FDA might impose the partial halt to vent its displeasure after the company was just granted expansion and reduced PFS gap by it; in this circumstance, it was no way the company could persuade the FDA to allow it to complete full enrolment unless the company strictly sticks to its agreed upon protocol change (2014), and it is equally no way the company would make the reason of halt public as it would inject uncertainty, fear to participating patients and thus compromise the trial.
If this is true, DMC seems obsolete or useless as the only thing it could do is to continually monitor the safety of the trial which can be replaced by CRO; in addition, one underlining reason for the disbanded DMC may also be due to its stubbornness to adapt to the new objectives.
So when the company decided to not fulfill full enrolment, it is natural FDA lifted the trial.
In consequences, it is still intact for the company to achieve both its initial objectives of PFS and OS (although I still suspect PFS failed in the only interim analysis conducted so far in 2015 due to pseudo progression (due to efficacy in reality as patients reacted strongly after administration of DCVax-L)), and additionally the full effect of DCVax-L as an immunization agent, i.e., the long and fat tail.
The company should be about ready to disclose the reason of the halt as we are approaching the final stage of unblinding.